181 related articles for article (PubMed ID: 24736462)
1. Endothelial progenitor cells and response to ranibizumab in age-related macular degeneration.
Scotti F; Maestroni A; Palini A; Introini U; Setaccioli M; Lorenzi M; Zerbini G
Retina; 2014 Sep; 34(9):1802-10. PubMed ID: 24736462
[TBL] [Abstract][Full Text] [Related]
2. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
[TBL] [Abstract][Full Text] [Related]
3. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
Ahn JK; Moon HJ
Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
[TBL] [Abstract][Full Text] [Related]
4. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
Machalińska A; Paczkowska E; Pabin T; Safranow K; Karczewicz D; Machaliński B
J Ocul Pharmacol Ther; 2011 Oct; 27(5):471-5. PubMed ID: 21830945
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
You JY; Chung H; Kim HC
Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
9. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.
Krishnan R; Goverdhan S; Lochhead J
Clin Exp Ophthalmol; 2009 May; 37(4):384-8. PubMed ID: 19594565
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
[TBL] [Abstract][Full Text] [Related]
12. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration.
Shin HJ; Chung H; Kim HC
Retina; 2013 May; 33(5):964-70. PubMed ID: 23348865
[TBL] [Abstract][Full Text] [Related]
13. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
15. Circulating endothelial and progenitor cells in age-related macular degeneration.
Mucciolo DP; Marcucci R; Sodi A; Cesari F; Murro V; Rogolino A; Rizzo S; Giusti B; Virgili G; Prisco D; Gori AM
Eur J Ophthalmol; 2020 Sep; 30(5):956-965. PubMed ID: 31328962
[TBL] [Abstract][Full Text] [Related]
16. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
17. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
18. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Bressler SB
Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Gupta B; Adewoyin T; Patel SK; Sivaprasad S
Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]